HOUSTON -- The tumor-derived vaccine vitespen (Oncophage) does not prevent kidney cancer recurrence or improve survival despite promising early results, researchers said.
vaccine therapyVaccine Therapy Disappoints for Kidney CancerMedPage Today Infectious Disease Thu, 07/03/2008 - 17:30
|
